Expert Point of View: Youn Kim, MD


Get Permission


Patients can respond in one lesion and not in another. It depends on where you sample.
— Youn Kim, MD

Tweet this quote

Commenting on this talk during the discussion afterward, Youn Kim, MD, of Stanford University School of Medicine, Stanford, California, said: “At our center, we use high-throughput sequencing of T-cell receptors daily in patients with cutaneous T-cell lymphomas, and it is a billable service paid by the insurance company. At Stanford, the high-throughput sequencing method has replaced standard polymerase chain reaction methods for molecular diagnosis. We also use it for posttransplant minimal residual disease monitoring in patients with cutaneous T-cell lymphomas as well.”

Dr. Kim cautioned that just because one skin lesion has no malignant clone, that may not mean the patient is in remission. “Patients can respond in one lesion and not in another,” she said. “It depends on where you sample.”■

Disclosure: Dr. Kim reported no potential conflicts of interest.


Related Articles

High-Throughput Sequencing of T-Cell Receptors May Transform Diagnosis and Treatment of Cutaneous T-Cell Lymphomas

High-throughput sequencing of T-cell receptors may be a solution to some of the challenges confronting oncologists who treat cutaneous T-cell lymphomas. According to experts who presented talks on high-throughput sequencing of T-cell receptors at the 3rd World Congress of Cutaneous Lymphoma...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.